IL148366A0 - Selective antagonists of a2b adenosine receptors - Google Patents

Selective antagonists of a2b adenosine receptors

Info

Publication number
IL148366A0
IL148366A0 IL14836600A IL14836600A IL148366A0 IL 148366 A0 IL148366 A0 IL 148366A0 IL 14836600 A IL14836600 A IL 14836600A IL 14836600 A IL14836600 A IL 14836600A IL 148366 A0 IL148366 A0 IL 148366A0
Authority
IL
Israel
Prior art keywords
adenosine receptors
selective antagonists
antagonists
selective
adenosine
Prior art date
Application number
IL14836600A
Other languages
English (en)
Original Assignee
Univ Vanderbilt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vanderbilt filed Critical Univ Vanderbilt
Publication of IL148366A0 publication Critical patent/IL148366A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
IL14836600A 1999-08-31 2000-08-28 Selective antagonists of a2b adenosine receptors IL148366A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15164999P 1999-08-31 1999-08-31
PCT/US2000/040751 WO2001016134A1 (en) 1999-08-31 2000-08-28 Selective antagonists of a2b adenosine receptors

Publications (1)

Publication Number Publication Date
IL148366A0 true IL148366A0 (en) 2002-09-12

Family

ID=22539669

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14836600A IL148366A0 (en) 1999-08-31 2000-08-28 Selective antagonists of a2b adenosine receptors
IL148366A IL148366A (en) 1999-08-31 2002-02-25 History of 3 - Isobutylxanthine - 8 - amino and their use as adenosine A2B receptor antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL148366A IL148366A (en) 1999-08-31 2002-02-25 History of 3 - Isobutylxanthine - 8 - amino and their use as adenosine A2B receptor antagonists

Country Status (22)

Country Link
EP (1) EP1208100B1 (zh)
JP (1) JP3914434B2 (zh)
KR (1) KR100502757B1 (zh)
CN (1) CN1178940C (zh)
AR (1) AR029178A1 (zh)
AT (1) ATE236160T1 (zh)
AU (1) AU760071B2 (zh)
BR (1) BR0013673A (zh)
CA (1) CA2383351C (zh)
DE (1) DE60001969T2 (zh)
DK (1) DK1208100T3 (zh)
ES (1) ES2190422T3 (zh)
HK (1) HK1049835B (zh)
IL (2) IL148366A0 (zh)
MX (1) MXPA02002262A (zh)
NO (1) NO328489B1 (zh)
NZ (1) NZ517546A (zh)
PT (1) PT1208100E (zh)
TR (1) TR200201132T2 (zh)
TW (1) TWI262921B (zh)
WO (1) WO2001016134A1 (zh)
ZA (1) ZA200201650B (zh)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403567B1 (en) 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US20020012946A1 (en) 2000-02-23 2002-01-31 Luiz Belardinelli Method of identifying partial agonists of the A2A receptor
US6770651B2 (en) 2001-06-29 2004-08-03 Venkata Palle A2B adenosine receptor antagonists
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
WO2005009445A1 (en) * 2003-07-22 2005-02-03 Cv Therapeutics, Inc. A1 adenosine receptor antagonists
WO2005053695A1 (ja) * 2003-12-04 2005-06-16 Eisai Co., Ltd. 多発性硬化症予防剤または治療剤
US7713982B2 (en) * 2004-02-14 2010-05-11 Smithkline Beecham Corporation Xanthines with HM74A receptor activity
JP2008516969A (ja) * 2004-10-15 2008-05-22 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ｂアデノシン受容体アンタゴニストを使用した、気道のリモデリングおよび肺の炎症の予防および処置の方法
JP2008517063A (ja) 2004-10-20 2008-05-22 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ａアデノシンレセプターアゴニストの使用
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
PL1989214T3 (pl) 2006-02-03 2017-07-31 Gilead Sciences, Inc. Proces otrzymywania agonisty receptora adenozynowego a2a i jego polimorfów
US7795427B2 (en) * 2006-02-14 2010-09-14 New York University Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
EP3389664A4 (en) * 2015-12-14 2020-01-08 Raze Therapeutics Inc. MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF
MX2021008094A (es) 2019-01-11 2021-09-21 Omeros Corp Metodos y composiciones para el tratamiento del cancer.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7810946L (sv) * 1978-10-20 1980-04-21 Draco Ab Metod att behandla kronisk obstruktiv luftvegssjukdom
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
WO1992011260A1 (en) * 1990-12-21 1992-07-09 Beecham Group Plc Xanthine derivatives
GB9210839D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds

Also Published As

Publication number Publication date
AU760071B2 (en) 2003-05-08
BR0013673A (pt) 2002-05-28
NO328489B1 (no) 2010-03-01
AU8034800A (en) 2001-03-26
CN1377352A (zh) 2002-10-30
HK1049835A1 (en) 2003-05-30
CA2383351C (en) 2005-11-01
NZ517546A (en) 2003-10-31
DK1208100T3 (da) 2003-06-30
TR200201132T2 (tr) 2002-08-21
KR20020041419A (ko) 2002-06-01
CA2383351A1 (en) 2001-03-08
ES2190422T3 (es) 2003-08-01
ZA200201650B (en) 2003-05-28
HK1049835B (zh) 2005-04-08
KR100502757B1 (ko) 2005-07-22
NO20020979D0 (no) 2002-02-27
EP1208100A1 (en) 2002-05-29
ATE236160T1 (de) 2003-04-15
JP2003508398A (ja) 2003-03-04
JP3914434B2 (ja) 2007-05-16
DE60001969D1 (de) 2003-05-08
AR029178A1 (es) 2003-06-18
DE60001969T2 (de) 2004-02-05
NO20020979L (no) 2002-04-26
IL148366A (en) 2006-12-10
EP1208100B1 (en) 2003-04-02
MXPA02002262A (es) 2002-09-30
CN1178940C (zh) 2004-12-08
TWI262921B (en) 2006-10-01
WO2001016134A1 (en) 2001-03-08
PT1208100E (pt) 2003-07-31

Similar Documents

Publication Publication Date Title
AU2875999A (en) Antagonists of a2b human adenosine receptors
HUP0401925A3 (en) A2b adenosine receptor antagonists
AU5316000A (en) Substituted 8-phenylxanthines useful as antagonists of a2b adenosine receptors
IL152726A0 (en) Adenosine a2a receptor antagonists
IL148366A0 (en) Selective antagonists of a2b adenosine receptors
IL161716A0 (en) ADENOSINE A2a RECEPTOR ANTAGONISTS
MXPA03004439A (es) Aminotiazoles y su uso como antagonistas del receptor de adenosina.
IS5706A (is) Adenosín A3 viðtakastillar
HK1044952B (zh) N-吡唑a2a受體激動劑
IL147195A0 (en) C-pyrazole a2a receptor agonists
HUP0202202A3 (en) Benzoxepino [2,3-b]pyridine derivatives and analogues as chemokine receptor antagonists and the use thereof
IL158214A0 (en) 8-heteroaryl xanthine adenosine a2b receptor antagonists
TWI365879B (en) A2b adenosine receptor antagonists
HUP0401437A3 (en) Adenosine a3 receptor agonists
HK1064097A1 (en) Bicyclic Ä1,2,4Ü -triazole adenosine a2a receptor antagonists
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
HUP0203371A3 (en) Adenosine receptor antagonists and methods of making and using the same
EP1061921A4 (en) VITRONECTIN RECEPTOR ANTAGONIST
AU3958902A (en) Crf receptor antagonists and methods relating thereto
PL370565A1 (en) 5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists
AU3167402A (en) Aminotriazolopyridiine derivatives as adenosine receptor ligands
AU2574801A (en) Selective iGLUR5 receptor antagonists
IL142362A0 (en) Ureidopiperidine derivatives as selective human nk3 receptor antagonists
EP1102587A4 (en) vitronectin receptor antagonists
GB0026327D0 (en) Thrombin receptor antagonists

Legal Events

Date Code Title Description
FF Patent granted